Raloxifene it is By this time used for prevention and processing osteoporosis in postmenopausal women. Some researches offer it in postmenopausal women in high risk of working out of a cancer of a breast, raloxifene can reduce risk to develop invasive hormonally - a sympathetic cancer of a breast (ER positive).

Raloxifene Was directly in comparison with tamoxifen in the big test including postmenopausal women in high risk of a cancer of a breast (named Research Tamoxifen and Raloxifene, or STAR test). Participants were postmenopausal women age 35 with risk of a cancer of a breast at least 1.66, how is defined by model Gail (look ‘ which should consider chemoprevention? ‘ more low, or previous history precancerous a chest condition, lobular carcinoma in a position (LCIS). Both tamoxifen and raloxifene were equally effective in prevention invasive a cancer of a breast but raloxifene had less effect on a uterus and lower risk of blood clots than tamoxifen [2]. Nevertheless, raloxifene only it is tested in postmenopausal women; advantage in premenopausal women the unknown.

Tags: Evista, Raloxifene

This entry was posted on Суббота, Январь 16th, 2010 at 12:22 and is filed under Woman Health, Woman health articles. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.